How we work

We constantly push ourselves in the pursuit of better – better solutions, better processes and better ways of working that help our clients navigate complexity and make better decisions with greater confidence

The Journey

We recognise that the journey is often as important as the destination. We work like an extension of your team so your overall journey with us feels better

The Journey

Our Values

Our culture is founded on a strong set of values that guide how we work with each other and our clients. We are a PASSIONATE team who believe in COLLABORATIVE SPIRIT and a CAN-DO attitude. We build BOLD solutions and make insightful recommendations because we dig deeper and remain CONSTANTLY CURIOUS, to provide positive challenge and FRESH THINKING

Our Values

Solving unique problems

Whether we are supporting you on your journey, or delivering specialist expertise, we are helping you make important choices

Job openings

With a global perspective

We work with 24 of the top 25 pharmaceutical companies as well as 100s of Biotechs globally from our offices in the US and Europe

Our locations

Teams of experts

We are expert navigators helping guide our clients to more successful outcomes

Our People

Expert Navigation

Explore case studies that bring to life how we’ve uncovered hidden insights, explored scientific options and helped make difficult strategic choices

Case studies
Silver Lining to Approval of Aducanumab?
Silver Lining to Approval of Aducanumab?
The accelerated and broad label approval of Biogen’s Alzheimer's Disease (AD) drug aducanumab (Aduhelm) is controversial (to say the least) on many fronts, ranging from:(1) validity of the amyloid biomarker data that formed the basis of approval(2) expansive label indicating all AD patients despite an extremely heterogenous population with differing levels of disease severity, disease progression and comorbidities(3) uncertainty amongst prescribers and patients and caregivers about which.
Next Wave AntiCancer Therapies Part 1
Next Wave AntiCancer Therapies Part 1
“In 1890, the Russian playwright and physician Anton Chekov wrote a letter in which he alluded to a centuries-old observation that infections seemed to slow the growth of malignant tumors.
Pharma perspective: Does the patient journey inform better strategy and enhance patient outcomes?
Pharma perspective: Does the patient journey inform better strategy and enhance patient outcomes?
Q&A with Pharma Progress 2021 panellist: Daniel De Schryver, Patient Engagement & Advocacy Lead, Europe, Middle-East and Africa, Janssen1.
Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA Approval
Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA Approval
A striking number of anticancer cellular immunotherapies, also commonly referred to as adoptive cellular therapies (ACT), are in various stages of development, either as monotherapies or in combination with other treatments.